US4894366A
(en)
*
|
1984-12-03 |
1990-01-16 |
Fujisawa Pharmaceutical Company, Ltd. |
Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
|
US5254562A
(en)
*
|
1984-12-03 |
1993-10-19 |
Fujisawa Pharmaceutical Company, Ltd. |
Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
|
US5266692A
(en)
*
|
1984-12-03 |
1993-11-30 |
Fujisawa Pharmaceutical Co., Ltd. |
Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
|
GB8608080D0
(en)
*
|
1986-04-02 |
1986-05-08 |
Fujisawa Pharmaceutical Co |
Solid dispersion composition
|
ATE98700T1
(de)
*
|
1987-06-05 |
1994-01-15 |
Fujisawa Pharmaceutical Co |
Anti-fr-900506-stoffe-antikoerper und hoechstempfindliches enzym-immunoassay-verfahren.
|
DE3737523A1
(de)
*
|
1987-11-05 |
1989-05-18 |
Bayer Ag |
Verwendung von substituierten hydroxypiperidinen als antivirale mittel
|
AT400808B
(de)
*
|
1987-11-09 |
1996-03-25 |
Sandoz Ag |
Verwendung von tricyclischen verbindungen zur herstellung von topischen arzneimitteln
|
PH26083A
(en)
*
|
1987-11-09 |
1992-02-06 |
Sandoz Ltd |
11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
|
DE3838035C2
(de)
*
|
1987-11-09 |
1994-03-24 |
Sandoz Ag |
Neue Verwendung von 11,28-dioxa-4-azatricyclo[22.3.1.O·4··,··9·]octacos-18-en-Derivaten
|
US5366971A
(en)
*
|
1987-11-09 |
1994-11-22 |
Sandoz Ltd. |
Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them
|
DE3844904C2
(de)
*
|
1987-11-09 |
1997-01-30 |
Sandoz Ag |
Neue Verwendung von 11,28-Dioxa-4-azatricyclo-[22.3.1.0·4·,·9·]octacos-18-en-Derivaten
|
ATE120466T1
(de)
|
1987-12-09 |
1995-04-15 |
Fisons Plc |
Makrozyklische verbindungen.
|
GB8728820D0
(en)
*
|
1987-12-09 |
1988-01-27 |
Fisons Plc |
Compounds
|
AT407957B
(de)
*
|
1987-12-17 |
2001-07-25 |
Novartis Erfind Verwalt Gmbh |
Neue verwendung von 11,28-dioxa-4-azatricyclo- (22.3.1.04,9)octacos-18-en-derivaten und sie enthaltende pharmazeutische zubereitungen
|
EP0323865A1
(fr)
*
|
1988-01-07 |
1989-07-12 |
Merck & Co. Inc. |
Agent immunopresseur
|
EP0349061B1
(fr)
*
|
1988-06-29 |
1995-03-29 |
Merck & Co. Inc. |
Agent immuno-suppresseur
|
US4981792A
(en)
*
|
1988-06-29 |
1991-01-01 |
Merck & Co., Inc. |
Immunosuppressant compound
|
US5290772A
(en)
*
|
1988-06-29 |
1994-03-01 |
Merck & Co., Inc. |
Immunosuppressant agent
|
EP0353678B1
(fr)
*
|
1988-08-01 |
1995-12-13 |
Fujisawa Pharmaceutical Co., Ltd. |
Dérivés FR-901154 et FR-901155, procédé pour leur production
|
US5202258A
(en)
*
|
1988-08-05 |
1993-04-13 |
Merck & Co., Inc. |
Immunosuppressant-producing culture
|
EP0356399A3
(fr)
*
|
1988-08-26 |
1991-03-20 |
Sandoz Ag |
Dérivés substitués du 4-azatricyclo (22.3.1.04.9) octacos-18-ène, leur préparation et les compositions pharmaceutiques les contenant
|
EP0358508A3
(fr)
*
|
1988-09-08 |
1991-03-20 |
Merck & Co. Inc. |
Composé immunosuppreseur
|
EP0364031B1
(fr)
*
|
1988-10-12 |
1992-12-23 |
Merck & Co. Inc. |
Procédé pour le réarrangement du composé FK-506 utilisant un hydroxide comme médiateur
|
CA1316916C
(fr)
*
|
1988-10-12 |
1993-04-27 |
David Askin |
Produit du rearrangement du fk-506 par l'entremise d'un hydroxyde
|
US4980466A
(en)
*
|
1988-10-12 |
1990-12-25 |
Merck & Co., Inc. |
Hydroxide mediated FK-506 rearrangement product
|
FR2639637A1
(fr)
*
|
1988-11-29 |
1990-06-01 |
Sandoz Sa |
Derives cycliques et leurs metabolites, leur preparation et leur utilisation comme medicaments
|
US4975372A
(en)
*
|
1989-01-13 |
1990-12-04 |
Merck & Co., Inc. |
Microbial transformation product of L-683,590
|
EP0378317A3
(fr)
*
|
1989-01-13 |
1990-11-28 |
Merck & Co. Inc. |
Produit de transformation microbienne L-679,934
|
US5268370A
(en)
*
|
1989-01-13 |
1993-12-07 |
Merck & Co., Inc. |
Microbial transformation product of L-679,934
|
EP0378320A3
(fr)
*
|
1989-01-13 |
1990-11-28 |
Merck & Co. Inc. |
Produit de transformation microbienne
|
EP0388152B1
(fr)
*
|
1989-03-15 |
1994-10-12 |
Merck & Co. Inc. |
Procédé de préparation d'un agent immunosuppressif (demethimmunomycine) mettant en oeuvre une souche mutante d'un microorganisme
|
US5272068A
(en)
*
|
1989-03-15 |
1993-12-21 |
Merck & Co., Inc. |
Process for producing immunosuppressant agent L-683942 by fermentation
|
EP0388153B1
(fr)
*
|
1989-03-15 |
1994-12-28 |
Merck & Co. Inc. |
Agent immunosuppressif
|
US4940797A
(en)
*
|
1989-03-23 |
1990-07-10 |
Merck & Co., Inc. |
Process for synthesis of FK-506 C10-C18 intermediates
|
US5155228A
(en)
*
|
1989-03-23 |
1992-10-13 |
Merck & Co., Inc. |
FK-506 C10-C18 process intermediates
|
EP0399579A1
(fr)
*
|
1989-04-21 |
1990-11-28 |
Merck & Co. Inc. |
Macrolides à activité immunosuppressive
|
US5068323A
(en)
*
|
1989-04-21 |
1991-11-26 |
Merck & Co., Inc. |
Thermally re-arranged FK-506 derivatives having immunosuppressant activity
|
US5057608A
(en)
*
|
1989-04-21 |
1991-10-15 |
Merck & Co., Inc. |
Immunoregulants, immunosuppressants, process to make ring expanded macrolide related to FK-506/FK-520
|
US5270187A
(en)
*
|
1989-05-05 |
1993-12-14 |
Merck & Co., Inc. |
Microbial transformation product
|
US4987139A
(en)
*
|
1989-05-05 |
1991-01-22 |
Merck & Co., Inc. |
FK-520 microbial transformation product
|
JPH0368583A
(ja)
*
|
1989-05-05 |
1991-03-25 |
Merck & Co Inc |
新規微生物変換物質
|
IE64214B1
(en)
*
|
1989-06-06 |
1995-07-26 |
Fujisawa Pharmaceutical Co |
Macrolides for the treatment of reversible obstructive airways diseases
|
US5138052A
(en)
*
|
1989-06-13 |
1992-08-11 |
Merck & Co., Inc. |
L-683,590 microbial transformation product
|
CA2018710A1
(fr)
*
|
1989-06-13 |
1990-12-13 |
Shieh-Shung T. Chen |
L-683590, produits de transformation microbienne
|
AU641410B2
(en)
*
|
1989-06-14 |
1993-09-23 |
Sandoz Ltd. |
Antiinflammatory and immunosuppressant triheterocyclic FK506-like compounds and processes for their preparation
|
US5164525A
(en)
*
|
1989-06-30 |
1992-11-17 |
Merck & Co., Inc. |
Synthetic process for fk-506 type macrolide intermediates
|
US5235066A
(en)
*
|
1989-06-30 |
1993-08-10 |
Merck & Co., Inc. |
FK-506 type macrolide intermediate
|
WO1991002736A1
(fr)
*
|
1989-08-18 |
1991-03-07 |
Fisons Plc |
Composes macrocycliques
|
EP0413532A3
(en)
*
|
1989-08-18 |
1991-05-15 |
Fisons Plc |
Macrocyclic compounds
|
US5011943A
(en)
*
|
1989-08-28 |
1991-04-30 |
Merck Frosst Canada, Inc. |
FK-506 C10 -C24 process intermediates
|
GR1001225B
(el)
*
|
1989-09-14 |
1993-06-30 |
Fisons Plc |
Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
|
US5215995A
(en)
*
|
1989-10-16 |
1993-06-01 |
Fujisawa Pharmaceutical Co., Ltd. |
Hair revitalizing agent
|
DE10299040I2
(de)
*
|
1989-11-09 |
2006-08-24 |
Novartis Ag |
Heteroatome enthaltende tricyclische Verbindungen
|
IE904050A1
(en)
*
|
1989-11-13 |
1991-05-22 |
Merck & Co Inc |
Aminomacrolides and derivatives having immunosuppressive¹activity
|
US5208228A
(en)
*
|
1989-11-13 |
1993-05-04 |
Merck & Co., Inc. |
Aminomacrolides and derivatives having immunosuppressive activity
|
GB8925797D0
(en)
*
|
1989-11-15 |
1990-01-04 |
Fisons Plc |
Compositions
|
EP0444829A3
(en)
*
|
1990-02-27 |
1992-06-03 |
Fisons Plc |
Immunosuppressive compounds
|
US5064835A
(en)
*
|
1990-03-01 |
1991-11-12 |
Merck & Co., Inc. |
Hydroxymacrolide derivatives having immunosuppressive activity
|
US5260301A
(en)
*
|
1990-03-01 |
1993-11-09 |
Fujisawa Pharmaceutical Co., Ltd. |
Pharmaceutical solution containing FK-506
|
JPH05504956A
(ja)
*
|
1990-03-12 |
1993-07-29 |
藤沢薬品工業株式会社 |
トリシクロ化合物
|
US5296489A
(en)
*
|
1990-03-13 |
1994-03-22 |
Fisons |
Immunosuppressive macrocyclic compounds
|
JPH05505798A
(ja)
*
|
1990-03-13 |
1993-08-26 |
フアイソンズ・ピーエルシー |
免疫抑制マクロ環状化合物
|
CA2040551A1
(fr)
*
|
1990-04-30 |
1991-10-31 |
Mark T. Goulet |
Derives de desoxymacrolide ayant une activite immunosuppressive
|
WO1991017754A1
(fr)
*
|
1990-05-11 |
1991-11-28 |
Fujisawa Pharmaceutical Co., Ltd. |
Procedes servant a traiter et a prevenir une inflammation des muqueuses et des vaisseaux sanguins en utilisant du fk 506 et des composes connexes
|
JPH05507915A
(ja)
*
|
1990-06-11 |
1993-11-11 |
藤沢薬品工業株式会社 |
特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのfk506等のマクロライド化合物の用途
|
US5643901A
(en)
*
|
1990-06-11 |
1997-07-01 |
Fujisawa Pharmaceutical Co., Ltd. |
Medicament for treating idiopathic thrombocytopenic purpura
|
US5210030A
(en)
*
|
1990-06-25 |
1993-05-11 |
Merck & Co., Inc. |
Process for selectively acylating immunomycin
|
US5342935A
(en)
*
|
1990-06-25 |
1994-08-30 |
Merck & Co., Inc. |
Antagonists of immunosuppressive macrolides
|
GB9014136D0
(en)
*
|
1990-06-25 |
1990-08-15 |
Fujisawa Pharmaceutical Co |
Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
|
US5190950A
(en)
*
|
1990-06-25 |
1993-03-02 |
Merck & Co., Inc. |
Antagonists of immunosuppressive macrolides
|
CA2044846A1
(fr)
*
|
1990-06-25 |
1991-12-26 |
Thomas R. Beattie |
Antagonistes de macrolides immunosuppresseurs
|
GB9014681D0
(en)
*
|
1990-07-02 |
1990-08-22 |
Fujisawa Pharmaceutical Co |
Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
|
MY110418A
(en)
*
|
1990-07-02 |
1998-05-30 |
Novartis Ag |
Heteroatoms-containing tricyclic compounds.
|
EP0466365A3
(en)
*
|
1990-07-03 |
1992-04-15 |
Merck & Co. Inc. |
Novel immunosuppressant fermentation products of a microorganism
|
GB2245891A
(en)
*
|
1990-07-09 |
1992-01-15 |
Fujisawa Pharmaceutical Co |
Tricyclo compounds
|
GB2246350A
(en)
*
|
1990-07-23 |
1992-01-29 |
Fujisawa Pharmaceutical Co |
Tricyclo compounds
|
US5089517A
(en)
*
|
1990-08-03 |
1992-02-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Neuroprotection by indolactam v and derivatives thereof
|
AU8394291A
(en)
*
|
1990-08-18 |
1992-03-17 |
Fisons Plc |
Macrocyclic compounds
|
GB2247620A
(en)
*
|
1990-09-07 |
1992-03-11 |
Fujisawa Pharmaceutical Co |
The use of macrolide compounds for cytomegalovirus infection
|
CA2051872A1
(fr)
*
|
1990-09-24 |
1992-03-25 |
Kevin M. Byrne |
Procede de biosynthese dirigee de la prolyl-immunomycine
|
GB2248184A
(en)
*
|
1990-09-28 |
1992-04-01 |
Fujisawa Pharmaceutical Co |
New use of macrolide compounds for active oxygen-mediated diseases
|
US5143918A
(en)
*
|
1990-10-11 |
1992-09-01 |
Merck & Co., Inc. |
Halomacrolides and derivatives having immunosuppressive activity
|
US5233036A
(en)
*
|
1990-10-16 |
1993-08-03 |
American Home Products Corporation |
Rapamycin alkoxyesters
|
US5348966A
(en)
*
|
1990-10-24 |
1994-09-20 |
Fujisawa Pharmaceutical Co., Ltd. |
Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds
|
CA2054128A1
(fr)
*
|
1990-10-29 |
1992-04-30 |
Kevin M. Byrne |
Procede de production d'analogues de l'immunomycine
|
PH31204A
(en)
*
|
1990-11-02 |
1998-05-05 |
Fujisawa Pharmaceutical Co |
Pharmaceutical composition.
|
CA2054983A1
(fr)
*
|
1990-11-08 |
1992-05-09 |
Sotoo Asakura |
Composition suspensible et procede de fabrication
|
GB2249787A
(en)
*
|
1990-11-19 |
1992-05-20 |
Fujisawa Pharmaceutical Co |
Lactone compounds
|
GB9027471D0
(en)
*
|
1990-12-19 |
1991-02-06 |
Fujisawa Pharmaceutical Co |
Novel compound
|
US5116756A
(en)
*
|
1991-01-28 |
1992-05-26 |
Merck & Co., Inc. |
Process for producing FK-506
|
US5194378A
(en)
*
|
1991-01-28 |
1993-03-16 |
Merck & Co., Inc. |
Process for producing fk-506
|
WO1992013862A1
(fr)
*
|
1991-02-05 |
1992-08-20 |
Fujisawa Pharmaceutical Co., Ltd. |
Composes de lactone
|
US5147877A
(en)
*
|
1991-04-18 |
1992-09-15 |
Merck & Co. Inc. |
Semi-synthetic immunosuppressive macrolides
|
DE69231644T2
(de)
*
|
1991-04-26 |
2001-05-23 |
Fujisawa Pharmaceutical Co., Ltd. |
Verwendung von makrolid-verbindungen gegen augenerkrankungen
|
US5250678A
(en)
*
|
1991-05-13 |
1993-10-05 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
|
US5162334A
(en)
*
|
1991-05-13 |
1992-11-10 |
Merck & Co., Inc. |
Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
|
US5565560A
(en)
*
|
1991-05-13 |
1996-10-15 |
Merck & Co., Inc. |
O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
|
US5262533A
(en)
*
|
1991-05-13 |
1993-11-16 |
Merck & Co., Inc. |
Amino O-aryl macrolides having immunosuppressive activity
|
CA2071066A1
(fr)
*
|
1991-06-19 |
1992-12-20 |
Ali Shafiee |
Produits de la methylation enzymatique ou microbienne
|
US5225403A
(en)
*
|
1991-06-25 |
1993-07-06 |
Merck & Co., Inc. |
C-21 hydroxylated FK-506 antagonist
|
US5273979A
(en)
*
|
1991-08-01 |
1993-12-28 |
Merck & Co., Inc. |
C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
|
US5198358A
(en)
*
|
1991-08-28 |
1993-03-30 |
Merck & Co., Inc. |
Microorganism for producing C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
|
US5149701A
(en)
*
|
1991-08-01 |
1992-09-22 |
Merck & Co., Inc. |
C-31 methylated FR-900520 cyclic hemiketal immunosuppressant agents
|
US5189042A
(en)
*
|
1991-08-22 |
1993-02-23 |
Merck & Co. Inc. |
Fluoromacrolides having immunosuppressive activity
|
US5708002A
(en)
*
|
1991-09-05 |
1998-01-13 |
Abbott Laboratories |
Macrocyclic immunomodulators
|
DE69232630T2
(de)
*
|
1991-09-05 |
2003-10-09 |
Abbott Laboratories, Abbott Park |
Makrocyclische immunmodulatoren
|
US5247076A
(en)
*
|
1991-09-09 |
1993-09-21 |
Merck & Co., Inc. |
Imidazolidyl macrolides having immunosuppressive activity
|
US5252732A
(en)
*
|
1991-09-09 |
1993-10-12 |
Merck & Co., Inc. |
D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
|
US5208241A
(en)
*
|
1991-09-09 |
1993-05-04 |
Merck & Co., Inc. |
N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
|
ZA926812B
(en)
|
1991-09-09 |
1993-04-28 |
Merck & Co Inc |
O-heteroaryl,o-alkylheteroaryl,o-alkenylheteroaryl and o-alkynylheteroaryl macrolides having immunosupressive activity
|
US5164495A
(en)
*
|
1991-09-18 |
1992-11-17 |
Abbott Laboratories |
Method for preparing a dicarboxylic acid half-acid ester of FK506
|
US5221625A
(en)
*
|
1992-01-10 |
1993-06-22 |
Merck & Co., Inc. |
Cyclcic FR-900520 microbial biotransformation agent
|
US5801144A
(en)
*
|
1992-01-28 |
1998-09-01 |
Karpas; Abraham |
Use of a compound for the manufacture of a medicament for the treatment of HIV infection
|
JP3140228B2
(ja)
*
|
1992-02-17 |
2001-03-05 |
ファイザー製薬株式会社 |
新規な大環状ラクトンおよびその生産菌
|
ATE159725T1
(de)
*
|
1992-03-02 |
1997-11-15 |
Pfizer |
2-aminozuckermakrolid-derivate
|
DE69310721T2
(de)
*
|
1992-03-02 |
1997-09-04 |
Pfizer |
Zuckerderivate von makroliden
|
ATE205496T1
(de)
*
|
1992-03-02 |
2001-09-15 |
Pfizer |
Desosamino-derivate von makroliden als immunosuppressive und antifungale mittel
|
US5612316A
(en)
*
|
1992-03-02 |
1997-03-18 |
Pfizer Inc. |
Fluorosugar derivatives of macrolides
|
ATE138807T1
(de)
|
1992-03-27 |
1996-06-15 |
American Home Prod |
29-demethoxyrapamycin zur induktion der immunosuppression
|
CA2091194A1
(fr)
*
|
1992-04-08 |
1993-10-09 |
Richard D. Connell |
Derives 2-oxoethyliques utilises comme immunosuppresseurs
|
HUT66531A
(en)
*
|
1992-05-07 |
1994-12-28 |
Sandoz Ag |
Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
|
WO1993025533A1
(fr)
*
|
1992-06-05 |
1993-12-23 |
Abbott Laboratories |
Procedes et reactifs pour le dosage d'immnosuppresseurs
|
US5284877A
(en)
*
|
1992-06-12 |
1994-02-08 |
Merck & Co., Inc. |
Alkyl and alkenyl macrolides having immunosuppressive activity
|
US5284840A
(en)
*
|
1992-06-12 |
1994-02-08 |
Merck & Co., Inc. |
Alkylidene macrolides having immunosuppressive activity
|
US5264355A
(en)
*
|
1992-07-02 |
1993-11-23 |
Merck & Co., Inc. |
Methlating enzyme from streptomyces MA6858
|
ZA935112B
(en)
*
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
US5324644A
(en)
*
|
1992-07-28 |
1994-06-28 |
Merck & Co., Inc. |
Process for producing immunosuppressant agent
|
ES2169068T3
(es)
*
|
1992-08-12 |
2002-07-01 |
Fujisawa Pharmaceutical Co |
Anticuerpo monoclonal que reconoce una proteina que se une a fk506, metodo para analizar el nivel de proteina que se une a fk506 y kit para ello.
|
US5365948A
(en)
*
|
1992-08-21 |
1994-11-22 |
J & W Mcmichael Software Inc. |
Method for use in treating a patient with FK 506 to prevent an adverse immune response
|
US5290689A
(en)
*
|
1992-09-28 |
1994-03-01 |
Merck & Co., Inc. |
New cyclic FR-900520 microbial biotransformation agent
|
US5283183A
(en)
*
|
1992-09-28 |
1994-02-01 |
Merck & Co., Inc. |
Cyclic FR-900520 microbial biotransformation agent
|
US5268281A
(en)
*
|
1992-09-28 |
1993-12-07 |
Merck & Co., Inc. |
Cyclic FR-900520 microbial biotransformation agent
|
US5268282A
(en)
*
|
1992-09-28 |
1993-12-07 |
Merck & Co., Inc. |
Cyclic FR-900520 microbial biotransformation agent
|
US5318895A
(en)
*
|
1992-10-05 |
1994-06-07 |
Merck & Co., Inc. |
Aspergillus niger mutants
|
GB9227055D0
(en)
*
|
1992-12-29 |
1993-02-24 |
Fujisawa Pharmaceutical Co |
New use
|
DE4300478C2
(de)
*
|
1993-01-11 |
1998-05-20 |
Eos Electro Optical Syst |
Verfahren und Vorrichtung zum Herstellen eines dreidimensionalen Objekts
|
EP0690713A4
(fr)
*
|
1993-03-17 |
1996-04-03 |
Abbott Lab |
Immunomodulateurs macrocycliques substitues contenant des amines alicycliques
|
AT408520B
(de)
*
|
1993-05-27 |
2001-12-27 |
Novartis Erfind Verwalt Gmbh |
Galenische formulierungen
|
MY110603A
(en)
*
|
1993-05-27 |
1998-08-29 |
Novartis Ag |
Tetrahydropyran derivatives
|
CH686761A5
(de)
*
|
1993-05-27 |
1996-06-28 |
Sandoz Ag |
Galenische Formulierungen.
|
GB2279006A
(en)
*
|
1993-06-03 |
1994-12-21 |
Fujisawa Pharmaceutical Co |
Treatment of amyotrophic lateral sclerosis
|
JPH06345646A
(ja)
*
|
1993-06-08 |
1994-12-20 |
Fujisawa Pharmaceut Co Ltd |
ローション剤
|
US5352783A
(en)
*
|
1993-06-09 |
1994-10-04 |
Merck & Co., Inc. |
Microbial transformation product having immunosuppressive activity
|
US5359060A
(en)
*
|
1993-07-06 |
1994-10-25 |
Pfizer, Inc. |
Phosponated derivatives of macrolides
|
CA2166892A1
(fr)
*
|
1993-07-30 |
1995-02-09 |
Yat Sun Or |
Macrolactames actives, agents immunoregulateurs
|
GB2281294A
(en)
*
|
1993-08-23 |
1995-03-01 |
Fujisawa Pharmaceutical Co |
Process for producing half esters of the macrolide FK506
|
US5616588A
(en)
|
1993-09-30 |
1997-04-01 |
American Home Products Corporation |
Rapamycin formulation for IV injection
|
UA41884C2
(uk)
*
|
1993-11-05 |
2001-10-15 |
Амерікан Хоум Продактс Корпорейшн |
Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
|
US5898029A
(en)
*
|
1994-04-12 |
1999-04-27 |
The John Hopkins University |
Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
|
US5880280A
(en)
*
|
1994-06-15 |
1999-03-09 |
Merck & Co., Inc. |
Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity
|
US5693648A
(en)
*
|
1994-09-30 |
1997-12-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
|
JP4155593B2
(ja)
|
1994-10-26 |
2008-09-24 |
ノバルティス・アクチエンゲゼルシャフト |
医薬組成物
|
AR004480A1
(es)
*
|
1995-04-06 |
1998-12-16 |
Amico Derin C D |
Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
|
US5616595A
(en)
*
|
1995-06-07 |
1997-04-01 |
Abbott Laboratories |
Process for recovering water insoluble compounds from a fermentation broth
|
WO1997010806A1
(fr)
*
|
1995-09-19 |
1997-03-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Compositions en aerosol
|
JP3942641B2
(ja)
|
1996-07-30 |
2007-07-11 |
ノバルティス アクチエンゲゼルシャフト |
サイクロスポリンaおよび40―o―(2―ヒドロキシエチル)―ラパマイシンを含む移植拒絶、自己免疫疾患または炎症性状態の処置用医薬組成物
|
KR100244164B1
(ko)
*
|
1997-07-15 |
2000-03-02 |
김용옥 |
수용성 고분자-타크로리무스 접합체 화합물 및 그의 제조 방법
|
US6562620B2
(en)
*
|
1997-09-19 |
2003-05-13 |
Mcgill University |
Medium to promote islet cell survival
|
US20030129215A1
(en)
|
1998-09-24 |
2003-07-10 |
T-Ram, Inc. |
Medical devices containing rapamycin analogs
|
US6890546B2
(en)
|
1998-09-24 |
2005-05-10 |
Abbott Laboratories |
Medical devices containing rapamycin analogs
|
US7399480B2
(en)
|
1997-09-26 |
2008-07-15 |
Abbott Laboratories |
Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
|
US6015815A
(en)
*
|
1997-09-26 |
2000-01-18 |
Abbott Laboratories |
Tetrazole-containing rapamycin analogs with shortened half-lives
|
US7357942B2
(en)
|
1997-09-26 |
2008-04-15 |
Abbott Laboratories |
Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
|
US8257725B2
(en)
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
US8394398B2
(en)
|
1997-09-26 |
2013-03-12 |
Abbott Laboratories |
Methods of administering rapamycin analogs with anti-inflammatories using medical devices
|
US8257726B2
(en)
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
|
US8057816B2
(en)
|
1997-09-26 |
2011-11-15 |
Abbott Laboratories |
Compositions and methods of administering paclitaxel with other drugs using medical devices
|
WO1999042104A1
(fr)
*
|
1998-02-23 |
1999-08-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Nouvel usage de composes de macrolides
|
AUPP223198A0
(en)
*
|
1998-03-06 |
1998-04-02 |
Fujisawa Pharmaceutical Co., Ltd. |
New use
|
TW570814B
(en)
|
1998-03-26 |
2004-01-11 |
Fujisawa Pharmaceutical Co |
Sustained-release pharmaceutical composition
|
EP1098897B1
(fr)
|
1998-07-17 |
2004-06-09 |
Agouron Pharmaceuticals, Inc. |
Composes, compositions et procedes de stimulation de la croissance et de l'allongement neuronaux
|
US7960405B2
(en)
|
1998-09-24 |
2011-06-14 |
Abbott Laboratories |
Compounds and methods for treatment and prevention of diseases
|
US7455853B2
(en)
|
1998-09-24 |
2008-11-25 |
Abbott Cardiovascular Systems Inc. |
Medical devices containing rapamycin analogs
|
US8257724B2
(en)
|
1998-09-24 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
US6503737B1
(en)
|
1998-10-02 |
2003-01-07 |
Kosan Biosciences, Inc. |
Isolated nucleic acids relating to the fkbA gene within the FK-520 polyketide synthase gene cluster
|
DE19853487A1
(de)
|
1998-11-19 |
2000-05-25 |
Fumapharm Ag Muri |
Verwendung von Dialkylfumaraten
|
GB9826656D0
(en)
|
1998-12-03 |
1999-01-27 |
Novartis Ag |
Organic compounds
|
CA2368463A1
(fr)
*
|
1999-03-31 |
2000-10-05 |
Abbott Laboratories |
Phosphate contenant des immunomodulateurs macrocycliques
|
US6121257A
(en)
*
|
1999-03-31 |
2000-09-19 |
Abbott Laboratories |
Sulfamate containing macrocyclic immunomodulators
|
US20060025388A1
(en)
*
|
1999-04-30 |
2006-02-02 |
Glick Gary D |
Compositions and methods relating to novel compounds and targets thereof
|
ATE258439T1
(de)
|
1999-04-30 |
2004-02-15 |
Univ Michigan |
Verwendung von benzodiazepinen zur behandlung von apoptose-induzierten autoimmunerkrankungen
|
US20040176358A1
(en)
*
|
1999-04-30 |
2004-09-09 |
The Regents Of The University Of Michigan |
Compositions and methods relating to novel compounds and targets thereof
|
US7063857B1
(en)
|
1999-04-30 |
2006-06-20 |
Sucampo Ag |
Use of macrolide compounds for the treatment of dry eye
|
US7144880B2
(en)
|
1999-04-30 |
2006-12-05 |
Regents Of The University Of Michigan |
Compositions relating to novel compounds and targets thereof
|
US20050113460A1
(en)
*
|
1999-04-30 |
2005-05-26 |
The Regents Of The University Of Michigan |
Compositions and methods relating to novel compounds and targets thereof
|
US20030119029A1
(en)
*
|
1999-04-30 |
2003-06-26 |
Regents Of The University Of Michigan |
Compositions and methods relating to novel benzodiazepine compounds and targets thereof
|
GB9917158D0
(en)
*
|
1999-07-21 |
1999-09-22 |
Fujisawa Pharmaceutical Co |
New use
|
US20030018044A1
(en)
*
|
2000-02-18 |
2003-01-23 |
Peyman Gholam A. |
Treatment of ocular disease
|
US6471980B2
(en)
|
2000-12-22 |
2002-10-29 |
Avantec Vascular Corporation |
Intravascular delivery of mycophenolic acid
|
US7018405B2
(en)
|
2000-12-22 |
2006-03-28 |
Avantec Vascular Corporation |
Intravascular delivery of methylprednisolone
|
AR033151A1
(es)
*
|
2001-04-12 |
2003-12-03 |
Sucampo Pharmaceuticals Inc |
Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
|
US6656460B2
(en)
|
2001-11-01 |
2003-12-02 |
Yissum Research Development |
Method and composition for dry eye treatment
|
US7452692B2
(en)
*
|
2002-02-13 |
2008-11-18 |
Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság |
Method for extracting a macrolide from biomatter
|
KR20040086369A
(ko)
*
|
2002-02-13 |
2004-10-08 |
비오갈 기오기스제르갸르 알티. |
바이오매터로부터 마크롤라이드를 추출하는 방법
|
WO2003072026A2
(fr)
*
|
2002-02-22 |
2003-09-04 |
3M Innovative Properties Company |
Procede visant a reduire et a traiter l'immunodepression induite par uv-b
|
AU2002321821A1
(en)
*
|
2002-06-28 |
2004-01-19 |
Biocon Limited |
Solid state fermentation and fed batch for the production of an immunosuppressant
|
BR0314013A
(pt)
|
2002-09-06 |
2005-07-12 |
Abbott Lab |
Equipamento médico contendo inibidor de hidratação
|
EP1594459B1
(fr)
|
2002-12-30 |
2010-02-17 |
Angiotech International Ag |
Liberation de medicaments a partir d'une composition polymere a gelification rapide
|
AU2003209664A1
(en)
*
|
2003-02-10 |
2004-08-30 |
Biocon Limited |
Solid state fermentation and fed batch for the production of an immunosuppressant
|
US20060169199A1
(en)
*
|
2003-03-31 |
2006-08-03 |
Vilmos Keri |
Crystallization and purification of macrolides
|
WO2004089958A2
(fr)
|
2003-03-31 |
2004-10-21 |
TEVA Gyógyszergyár Részvénytársaság |
Cristallisation et purification de macrolides
|
WO2005004848A1
(fr)
*
|
2003-07-09 |
2005-01-20 |
Chong Kun Dang Pharmaceutical Corp. |
Dispersion solide de tacrolimus
|
ES2297481T3
(es)
*
|
2003-07-24 |
2008-05-01 |
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag |
Metodo para purificar macrolidos.
|
WO2005011796A1
(fr)
*
|
2003-08-05 |
2005-02-10 |
Kaneka Corporation |
Stent a mettre en place in vivo
|
AU2004267910B2
(en)
|
2003-08-29 |
2011-01-06 |
Veloxis Pharmaceuticals, Inc. |
Solid dispersions comprising tacrolimus
|
ES2376238T3
(es)
|
2003-08-29 |
2012-03-12 |
Veloxis Pharmaceuticals A/S |
Composiciones de liberación modificada comprendiendo tacrolimus.
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
WO2005038009A2
(fr)
*
|
2003-10-17 |
2005-04-28 |
Ranbaxy Laboratories Limited |
Production de tacrolimus (fk-506) au moyen de nouvelles especes de streptomyces
|
AU2004292445B2
(en)
|
2003-11-21 |
2010-02-04 |
Zalicus Inc. |
Methods and reagents for the treatment of inflammatory disorders
|
EP1697383B1
(fr)
*
|
2003-12-05 |
2014-04-23 |
Biocon Limited |
Procédé de purification de tacrolimus
|
KR100485877B1
(ko)
*
|
2003-12-30 |
2005-04-28 |
종근당바이오 주식회사 |
타크롤리무스를 생산하는 미생물 및 이를 이용한타크롤리무스의 대량 생산방법
|
US20050176080A1
(en)
*
|
2004-02-10 |
2005-08-11 |
Vani Bodepudi |
Hapten, immunogens and derivatives of ascomycin useful for preparation of antibodies and immunoassays
|
EP1735042B1
(fr)
|
2004-03-19 |
2011-11-23 |
Abbott Laboratories |
Administration de medicaments multiples a partir d'un ballonnet et d'une prothese
|
US8431145B2
(en)
|
2004-03-19 |
2013-04-30 |
Abbott Laboratories |
Multiple drug delivery from a balloon and a prosthesis
|
WO2005098011A1
(fr)
|
2004-04-12 |
2005-10-20 |
Biocon Limited |
Procede de production de macrolides au moyen d'une nouvelle souche de streptomyces espece bicc 7752
|
US20090275099A1
(en)
*
|
2004-04-27 |
2009-11-05 |
Regents Of The University Of Michigan |
Methods and compositions for treating diseases and conditions associated with mitochondrial function
|
US20050272723A1
(en)
*
|
2004-04-27 |
2005-12-08 |
The Regents Of The University Of Michigan |
Methods and compositions for treating diseases and conditions associated with mitochondrial function
|
JP2006014722A
(ja)
*
|
2004-06-02 |
2006-01-19 |
Keio Gijuku |
遺伝子マーカー及びその利用
|
CA2571710A1
(fr)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
|
AU2005326322B2
(en)
*
|
2004-07-01 |
2009-02-05 |
Yale University |
Targeted and high density drug loaded polymeric materials
|
US20060014677A1
(en)
*
|
2004-07-19 |
2006-01-19 |
Isotechnika International Inc. |
Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
|
US20060052369A1
(en)
*
|
2004-09-07 |
2006-03-09 |
The Regents Of The University Of Michigan |
Compositions and methods relating to novel compounds and targets thereof
|
WO2006031661A2
(fr)
*
|
2004-09-10 |
2006-03-23 |
Ivax Pharmaceuticals S.R.O. |
Procede d'isolement de composes macrolides
|
KR20070057910A
(ko)
*
|
2004-09-10 |
2007-06-07 |
아이박스 파마슈티컬스 에스.알.오. |
결정질 타크롤리무스의 분리 방법
|
GT200500282A
(es)
*
|
2004-10-12 |
2006-05-04 |
|
Heteroatomos conteniendo compuestos triciclicos.
|
ITMI20042098A1
(it)
*
|
2004-11-03 |
2005-02-03 |
Antibioticos Spa |
Processo per la purificazione di tacrolimus
|
KR20070060144A
(ko)
|
2004-12-01 |
2007-06-12 |
테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 |
결정체 마크로라이드의 제조 방법
|
EP1835889A1
(fr)
*
|
2004-12-15 |
2007-09-26 |
Elan Pharma International Limited |
Formulations renfermant des nanoparticules de tacrolimus
|
US20060142565A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Vilmos Keri |
Method of purifying tacrolimus
|
US7638624B2
(en)
*
|
2005-01-03 |
2009-12-29 |
The Regents Of The University Of Michigan |
Compositions and methods relating to novel benzodiazepine compounds and derivatives
|
MX2007006119A
(es)
*
|
2005-01-05 |
2007-07-19 |
Teva Gyogyszergyar Zartkoruen |
Tacrolimus amorfo y preparacion de el.
|
ATE532064T1
(de)
*
|
2005-01-13 |
2011-11-15 |
Univ Keio |
Genmarker und dessen verwendung
|
ATE533520T1
(de)
|
2005-03-23 |
2011-12-15 |
Abbott Lab |
Abgabe von stark lipophilen mitteln durch medizinprodukte
|
JP5242374B2
(ja)
|
2005-03-23 |
2013-07-24 |
アボット・ラボラトリーズ |
組成物ならびに長期効力を得るための医療機器を用いたラパマイシン類縁体の投与方法
|
JP2008545757A
(ja)
|
2005-06-01 |
2008-12-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
溶媒和されていないベンゾジアゼピン組成物および方法
|
CN1876822B
(zh)
*
|
2005-06-06 |
2010-05-12 |
上海市农药研究所 |
他克莫司的产生菌株及生产方法
|
WO2007013017A1
(fr)
*
|
2005-07-29 |
2007-02-01 |
Ranbaxy Laboratories Limited |
Processus de purification de macrolides
|
ITMI20051549A1
(it)
*
|
2005-08-05 |
2007-02-06 |
Antibioticos Spa |
Purificazione del tacrolimus su supporti dimorigine vegetale
|
WO2007029082A2
(fr)
*
|
2005-09-05 |
2007-03-15 |
Ranbaxy Laboratories Limited |
Procede de fermentation ameliore pour la preparation d'ascomycine
|
US20080318289A1
(en)
*
|
2005-10-05 |
2008-12-25 |
Parveen Kumar |
Fermentation Processes for the Preparation of Tacrolimus
|
US20070105844A1
(en)
*
|
2005-10-26 |
2007-05-10 |
Regents Of The University Of Michigan |
Therapeutic compositions and methods
|
JP5241501B2
(ja)
|
2005-11-01 |
2013-07-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
治療特性を有する新規の1,4−ベンゾジアゼピン−2,5−ジオン
|
NZ568694A
(en)
|
2005-11-09 |
2011-09-30 |
Zalicus Inc |
Method, compositions, and kits for the treatment of medical conditions
|
US7678901B2
(en)
|
2006-02-28 |
2010-03-16 |
Wyeth |
Rapamycin analogs containing an antioxidant moiety
|
US7622477B2
(en)
|
2006-02-28 |
2009-11-24 |
Cordis Corporation |
Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
|
JP4700022B2
(ja)
*
|
2006-03-15 |
2011-06-15 |
アイバックス ファーマシューティカルズ スポレツノスト エス ルチェニム オメゼニム |
タクロリマスの精製方法
|
US8022188B2
(en)
*
|
2006-04-24 |
2011-09-20 |
Abbott Laboratories |
Immunosuppressant binding antibodies and methods of obtaining and using same
|
US7759338B2
(en)
*
|
2006-04-27 |
2010-07-20 |
The Regents Of The University Of Michigan |
Soluble 1,4 benzodiazepine compounds and stable salts thereof
|
MX2008015488A
(es)
|
2006-06-09 |
2009-02-12 |
Univ Michigan |
Composiciones y metodos relacionados con compuestos novedosos y objetivos de los mismos.
|
CA2660804A1
(fr)
|
2006-08-31 |
2008-03-06 |
Astellas Pharma Inc. |
Vesicule de lipide a ciblage inverse
|
WO2008033466A2
(fr)
*
|
2006-09-14 |
2008-03-20 |
Combinatorx (Singapore) Pre. Ltd. |
Compositions et procédés pour le traitement de maladies virales
|
EP1960406A2
(fr)
*
|
2006-11-06 |
2008-08-27 |
TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság |
Ascomycine et pimécrolimus ayant des niveaux réduits de desméthylascomycine et de 32-désoxy-32-épichloro-desméthylascomycine respectivement, et leurs procédés de préparation
|
EP2124898B1
(fr)
|
2007-01-10 |
2013-08-14 |
Board of Regents, The University of Texas System |
Administration amelioree de compositions medicamenteuses immunosuppressives par voie pulmonaire
|
US10265407B2
(en)
|
2007-02-15 |
2019-04-23 |
Yale University |
Modular nanodevices for smart adaptable vaccines
|
WO2008109347A2
(fr)
*
|
2007-03-02 |
2008-09-12 |
Yale University |
Procédés d'administration ex vivo de médicaments à des greffons en utilisant des nanoparticules polymères
|
WO2008112553A1
(fr)
|
2007-03-09 |
2008-09-18 |
The Regents Of The University Of Michigan |
Compositions et procédés en rapport avec de nouveaux composés et cibles de ceux-ci
|
LT2167033T
(lt)
|
2007-05-30 |
2017-08-10 |
Veloxis Pharmaceuticals A/S |
Kartą per dieną vartojama geriamoji vaisto forma, apimanti takrolimą
|
KR100891313B1
(ko)
|
2007-08-17 |
2009-03-31 |
(주) 제노텍 |
담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법
|
WO2009036175A2
(fr)
|
2007-09-14 |
2009-03-19 |
The Regents Of The University Of Michigan |
Inhibiteur de f1f0-atpase et procédés associés
|
CN101918375A
(zh)
|
2007-11-06 |
2010-12-15 |
密歇根大学董事会 |
在皮肤病症的治疗中有用的苯并二氮杂*酮化合物
|
CA2711765A1
(fr)
*
|
2008-01-11 |
2009-07-16 |
Massachusetts Eye & Ear Infirmary |
Animaux transgeniques de caspase dimerisable d'arret conditionnel
|
KR101003042B1
(ko)
|
2008-03-17 |
2010-12-21 |
종근당바이오 주식회사 |
고순도 타크로리무스의 정제 방법
|
AU2009233906A1
(en)
*
|
2008-04-08 |
2009-10-15 |
Amyris, Inc. |
Expression of heterologous sequences
|
US9549918B2
(en)
|
2008-05-30 |
2017-01-24 |
Veloxis Pharmaceuticals A/S |
Stabilized tacrolimus composition
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
WO2010021681A2
(fr)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions et procédés pour le traitement de maladies virales
|
JP5567573B2
(ja)
|
2008-09-11 |
2014-08-06 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
アリールグアニジンf1f0−atpアーゼ阻害剤およびそれと関連する方法
|
KR100910165B1
(ko)
|
2008-09-18 |
2009-07-30 |
(주) 제노텍 |
은 이온 용액 추출을 이용한 불포화 알킬기를 가진 락톤 화합물 정제방법
|
CA2738831C
(fr)
*
|
2008-10-08 |
2016-05-24 |
Takata Seiyaku Co., Ltd. |
Preparation de tacrolimus pour applications externes
|
NZ593647A
(en)
|
2008-12-23 |
2013-08-30 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
AU2009329867B2
(en)
|
2008-12-23 |
2015-01-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
CN102753563A
(zh)
|
2008-12-23 |
2012-10-24 |
吉利德制药有限责任公司 |
核苷类似物
|
WO2010121164A2
(fr)
|
2009-04-17 |
2010-10-21 |
The Regents Of The University Of Michigan |
Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
|
CN101712686B
(zh)
*
|
2009-06-22 |
2012-08-29 |
鲁南制药集团股份有限公司 |
一种发酵液中他克莫司的分离纯化方法
|
EP2272963A1
(fr)
*
|
2009-07-09 |
2011-01-12 |
LEK Pharmaceuticals d.d. |
Procédé de préparation d'un tacrolimus
|
WO2011035124A1
(fr)
|
2009-09-18 |
2011-03-24 |
The Regents Of The University Of Michigan |
Composés de benzodiazépinone et méthodes de traitement les utilisant
|
WO2011062765A2
(fr)
|
2009-11-17 |
2011-05-26 |
The Regents Of The University Of Michigan |
1,4-benzodiazépine-2,5-diones et composés apparentés présentant des propriétés thérapeutiques
|
CN102753544A
(zh)
|
2009-11-17 |
2012-10-24 |
密执安大学评议会 |
具有治疗性能的1,4-苯并二氮杂*-2,5-二酮和相关化合物
|
US20110130711A1
(en)
*
|
2009-11-19 |
2011-06-02 |
Follica, Inc. |
Hair growth treatment
|
US8951595B2
(en)
|
2009-12-11 |
2015-02-10 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable molecular architecture for drug-coated balloon
|
US8480620B2
(en)
|
2009-12-11 |
2013-07-09 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable solubility profile for drug-coated balloon
|
BR112012024884A2
(pt)
|
2010-03-31 |
2016-10-18 |
Gilead Pharmasset Llc |
síntese estereosseletiva de ativos contendo fósforo
|
US20110318277A1
(en)
|
2010-06-25 |
2011-12-29 |
APT Pharmaceuticals, Inc. University of Maryland, Baltimore |
Tacrolimus compositions for aerosol administration
|
KR101261131B1
(ko)
|
2010-08-24 |
2013-05-06 |
이화여자대학교 산학협력단 |
신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주
|
MA34586B1
(fr)
|
2010-08-25 |
2013-10-02 |
Medis Lab |
Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees
|
US10117411B2
(en)
|
2010-10-06 |
2018-11-06 |
Dow Agrosciences Llc |
Maize cytoplasmic male sterility (CMS) C-type restorer RF4 gene, molecular markers and their use
|
ES2733646T3
(es)
|
2011-03-11 |
2019-12-02 |
Beth Israel Deaconess Medical Ct Inc |
Anticuerpos anti-CD40 y usos de los mismos
|
EP2841098A4
(fr)
|
2012-04-23 |
2016-03-02 |
Allertein Therapeutics Llc |
Nanoparticules pour le traitement d'allergies
|
US8669281B1
(en)
|
2013-03-14 |
2014-03-11 |
Alkermes Pharma Ireland Limited |
Prodrugs of fumarates and their use in treating various diseases
|
DK2970101T3
(en)
|
2013-03-14 |
2018-08-20 |
Alkermes Pharma Ireland Ltd |
PRO-DRUGS OF FUMARATES AND THEIR USE IN TREATING DIFFERENT DISEASES
|
JP2016516754A
(ja)
|
2013-04-03 |
2016-06-09 |
アラーテイン・セラピューティクス・リミテッド・ライアビリティ・カンパニーAllertein Therapeutics, LLC |
新規のナノ粒子組成物
|
WO2015073691A1
(fr)
|
2013-11-14 |
2015-05-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Procédés pour traiter le cancer par activation de la signalisation bmp
|
CN104650112B
(zh)
*
|
2013-11-18 |
2018-07-31 |
山东新时代药业有限公司 |
他克莫司8-丙基类似物的制备方法
|
UY35927A
(es)
|
2013-12-31 |
2015-07-31 |
Dow Agrosciences Llc |
?gen restaurador rf3 de tipo s de la esterilidad masculina citoplasmática del maíz (cms), marcadores moleculares y sus usos?.
|
CA2935801A1
(fr)
|
2014-01-13 |
2015-07-16 |
Amplyx Pharmaceuticals, Inc. |
Composes antifongiques
|
EP3094314B1
(fr)
|
2014-01-16 |
2021-06-23 |
MUSC Foundation For Research Development |
Nanosupports ciblés pour l'administration d'agents immunosuppresseurs
|
AU2015218587B2
(en)
|
2014-02-24 |
2017-04-27 |
Alkermes Pharma Ireland Limited |
Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
|
KR101694879B1
(ko)
*
|
2014-08-01 |
2017-01-12 |
주식회사 인트론바이오테크놀로지 |
면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
|
EP3977995A1
(fr)
|
2014-10-28 |
2022-04-06 |
Koushi Yamaguchi |
Tacrolimus pour améliorer les conditions de la grossesse
|
WO2017031105A1
(fr)
|
2015-08-19 |
2017-02-23 |
Selten Pharma, Inc. |
Formulations pharmaceutiques
|
CA3002789A1
(fr)
|
2015-09-04 |
2017-03-09 |
Primatope Therapeutics Inc. |
Anticorps humanises anti-cd40 et leurs utilisations
|
CN106074367A
(zh)
*
|
2016-07-20 |
2016-11-09 |
中山大学中山眼科中心 |
含fk506类化合物/fkbp蛋白二聚体的药物组合物及其制备方法
|
CN108384819B
(zh)
*
|
2017-02-03 |
2021-06-25 |
上海医药工业研究院 |
一种用于发酵他克莫司的培养基以及发酵方法
|
RU2686779C1
(ru)
*
|
2018-07-26 |
2019-04-30 |
Общество с ограниченной ответственностью "Изварино Фарма" |
Штамм streptomyces tsukubensis - продуцент такролимуса и способ получения такролимуса
|
US20210228551A1
(en)
|
2018-08-10 |
2021-07-29 |
Koushi Yamaguchi |
Therapeutic agent for humoral immunity-related diseases in maternofetal relationship
|
WO2020076738A2
(fr)
*
|
2018-10-12 |
2020-04-16 |
Bellicum Pharmaceuticals, Inc |
Composés à liaison protéinique
|
WO2020117134A1
(fr)
|
2018-12-04 |
2020-06-11 |
İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. |
Formulation de pommade à base de tacrolimus stable pour le traitement topique d'affections cutanées
|
EP3900729A4
(fr)
|
2018-12-18 |
2022-09-07 |
Koushi Yamaguchi |
Agent permettant de traiter l'infertilité, les fausses couches récurrentes et d'améliorer la grossesse
|
KR102135527B1
(ko)
*
|
2018-12-18 |
2020-07-20 |
이문수 |
발가락 습기 제거 양말
|
GR1009790B
(el)
|
2019-03-20 |
2020-08-03 |
Φαρματεν Α.Β.Ε.Ε. |
Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους
|
CN117177749A
(zh)
|
2021-03-03 |
2023-12-05 |
萨那生物科技公司 |
与心肌细胞疗法一起使用的免疫抑制疗法以及相关的方法和组合物
|